Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population

Zena and Michael Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, NY, USA.
Journal of Thrombosis and Haemostasis (Impact Factor: 5.72). 05/2010; 8(5):1018-26. DOI: 10.1111/j.1538-7836.2010.03792.x
Source: PubMed


Gene-based warfarin dosing algorithms have largely been developed in homogeneous populations, and their generalizability has not been established.
We sought to assess the performance of published algorithms in a racially diverse and multiethnic sample, and determine if additional clinical variables or genetic variants associated with dose could enhance algorithm performance.
In 145 compliant patients on warfarin with a goal international normalized ratio (INR) of 2-3, stable, therapeutic doses were compared with predicted doses using 12 reported algorithms that incorporated CYP2C9 and VKORC1 variants. Additional covariates tested with each model included race, concurrent medications, medications known to interact with warfarin and previously described CYP4F2, CALU and GGCX variants.
The mean patient age was 67 +/- 14 years; 90 (62%) were male. Eighty-two (57%) were Caucasian, 28 (19%) African-American, 20 (14%) Hispanic and 15 (10%) Asian. The median warfarin dose was 35 mg per week (interquartile range 23-53 mg per week). Gene-based dosing algorithms explained 37-55% of the variation in warfarin dose requirements. Neither the addition of race, number of concurrent medications nor the number of concurrent medications interacting with warfarin enhanced algorithm performance. Similarly, consideration of CYP4F2, CALU or GGCX variant genotypes did not improve algorithms.
Existing gene-based dosing algorithms explained between approximately one-third and one-half of the variability in warfarin dose requirements in this racially and ethnically diverse cohort. Additional clinical and recently described genetic variants associated with warfarin dose did not enhance prediction in our patient population.

Download full-text


Available from: Malgorzata Jaremko, Mar 23, 2015
  • Source
    • "Study name Caldwell MD et al . 2008 ( Florida : Black ) Cavallari LH et al . 2010 Lubitz SA et al . 2010 ( African - Americans )"
    [Show abstract] [Hide abstract]
    ABSTRACT: A systematic review and a meta-analysis were performed to quantify the accumulated information from genetic association studies investigating the impact of the CYP4F2 rs2108622 (p.V433M) polymorphism on coumarin dose requirement. An additional aim was to explore the contribution of the CYP4F2 variant in comparison with, as well as after stratification for, the VKORC1 and CYP2C9 variants. Thirty studies involving 9,470 participants met prespecified inclusion criteria. As compared with CC-homozygotes, T-allele carriers required an 8.3% (95% confidence interval (CI): 5.6-11.1%; P < 0.0001) higher mean daily coumarin dose than CC homozygotes to reach a stable international normalized ratio (INR). There was no evidence of publication bias. Heterogeneity among studies was present (I(2) = 43%). Our results show that the CYP4F2 p.V433M polymorphism is associated with interindividual variability in response to coumarin drugs, but with a low effect size that is confirmed to be lower than those contributed by VKORC1 and CYP2C9 polymorphisms.Clinical Pharmacology & Therapeutics (2012); advance online publication 7 November 2012. doi:10.1038/clpt.2012.184.
    Clinical Pharmacology &#38 Therapeutics 11/2012; 92(6). DOI:10.1038/clpt.2012.184 · 7.90 Impact Factor
  • Source
    • "Genotype-guided dosing has received increasing attention as a potentially useful strategy to improve the efficacy and safety of coumarins. Pharmacogenetically-guided dosing formulas have been developed to predict the coumarin maintenance dose [10, 11]. Most of these studies focussed on warfarin, the most widely used coumarin worldwide. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The anticoagulation response to vitamin K antagonists is characterised by high inter-individual variability. The impact of single nucleotide polymorphisms (SNPs) in several genes of enzymes involved in the vitamin K cycle on phenprocoumon dose variability and phenprocoumon plasma concentrations is still under investigation. We assessed the influence of VKORC1 c.-1639G>A, CYP2C9*2, CYP2C9*3, CYP4F2 c.1297G>A, CALU c.*4A>G, EPHX1 c.337T>C, GGCX c.214+597G>A, F7 c.-402G>A, F7 c.-401G>T, PROC c.-228C>T and PROC c.-215G>A along with clinical and demographic parameters on steady-state phenprocoumon therapy in 75 patients. A prediction model was developed for total phenprocoumon plasma concentrations and daily phenprocoumon doses required for therapeutic anticoagulation. The VKORC1 c.-1639 genotype was the main predictor of the phenprocoumon daily dose (adjusted R(2) = 37.6%) and the total phenprocoumon concentration (adjusted R(2) = 38.3%). CYP2C9 affected the phenprocoumon concentration, but not the dose requirements. SNPs in the other genes of the vitamin K cycle, concomitant medication, nicotine use and alcohol consumption did not predict phenprocoumon concentrations and phenprocoumon dose requirements in a multiple linear regression model. Phenprocoumon concentrations were predicted by VKORC1 c.-1639, CYP2C9 genotype, age and BMI. The final prediction model for the daily phenprocoumon dose requirements comprised VKORC1 c.-1639 genotype, age and height accounting for 48.6% of the inter-individual variability. A rough prediction of phenprocoumon maintenance doses can be achieved by a limited set of parameters (VKORC1, age, height). The investigated SNPs in CYP4F2, CALU, EPHX1, GGCX, F7, and PROC did not improve the predictive value of a pharmacogenetic-based dosing equation for phenprocoumon.
    European Journal of Clinical Pharmacology 11/2010; 67(4):371-81. DOI:10.1007/s00228-010-0950-y · 2.97 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Time-dependent-dielectric-breakdown (TDDB) distributions obtained from oxides of the same physical geometry and stressed at the same electric field were found to shift to shorter times when the amount of energy available to flow through electric breakdowns was increased. This paper shows that TDDB distributions are nonunique and that for a breakdown model to accurately describe the reliability of an oxide during actual use conditions, the oxide thermal geometry must be taken into account. An accurate method of obtaining electric breakdown distributions is also presented which allows the use of smaller sample sizes to obtain time-dependent-electric-breakdown (TDEB) distributions which are similar to TDDB distributions
    Integrated Reliability Workshop Final Report, 1997 IEEE International; 11/1997
Show more